X-linked recessive myotubular myopathy (XLMTM) is a very severe congenital muscular disease characterised by an impaired maturation of muscle fibres, and caused by defects in the MTM1 gene. This gene defines a new family of putative tyrosine phosphatases conserved through evolution. We have determined intronic flanking sequences for all the 15 exons to facilitate the detection of mutations in patients and genetic counselling. We characterised a new polymorphic marker in the immediate vicinity of the gene, which might prove useful for linkage analysis. Sequencing of the TATA-less predicted promoter provides the basis for transcriptional regulatory studies.
Introduction
X-linked recessive myotubular myopathy (XLMTM OMIM31040) is a very severe congenital muscular disease characterised by hypotonia and generalised muscle weakness in newborn males. Most patients die within the first months of life. Characteristic muscle histopathology consists of small rounded muscle cells with centrally located nuclei resembling foetal myotubes and it has been suggested that the disorder results from an arrest in the normal development of muscle fibres, probably during late myogenesis. 1 The locus responsible for the disease (MTM1) was mapped to proximal Xq28 by linkage analysis and the candidate region was restricted by analysing recombination events and patients carrying deletions. 2, 3 We have recently reported the identification of the MTM1 gene by positional cloning. 4 It encodes a protein (myotubularin) with a putative tyrosine phosphatase domain (PTP). Tyrosine phosphatases have been shown to be involved in transduction pathways controlling cell growth and differentiation. 5 Myotubularin is highly conserved through evolution and several homologous human genes were found, which define a new family of putative tyrosine phosphatases in man.
In this study we have determined the complete exonintron structure of the human MTM1 gene and 2.7 kb of upstream sequences in 5'. This information is very useful for the characterisation of mutations in XLMTM patients, a prerequisite for reliable genetic counselling and determination of carrier status. 6 A new polymorphic marker, located less than 3 kb upstream from the MTM1 gene, may allow a more reliable linkage analysis in familial cases. Four  cosmids  (ICRF  C104-H05147,  C104-E03147,  C104-B03151 and a Xq28 specific library cosmid Qc3A3) were subcloned as described. 3 Subclones were screened by hybridisation with radioactively labelled cDNAs or oligonucleotides, and by PCR, for the presence of MTM1 exons and further sequenced with exon specific primers. As exons 5 to 8 were not included in our cosmid contig, PCR and long-range PCR from genomic DNA was performed with exonic primers, to clone introns 4, 5, 6, 7 and 8. For long-range PCR analysis of intron sizes, 300 ng of genomic DNA was amplified using the Expand Long Template PCR System kit (Boehringer Mannheim, Meylan, France) for 30 cycles with an elongation time ranging from 4 to 15 minutes, and to assess their size more precisely each product was digested with Bam HI, Cla I, Hpa I, Pvu II and Sac I and compared to size marker (from Boehringer Mannheim, Meylan, France) ( Figure 1 ). Longrange PCR was unable to amplify intron 1 and its size was estimated from hybridisation experiments using specific probes from exons 1 and 2 on the previously characterised cosmid contig, digested with Bam HI and BglII or EcoRI. Exon 1 is present in cosmid Qc3A3 from a Xq28 library, while exon 2 is present in the overlapping cosmid C104-B03151 from Lawrence Livermore National Laboratories. 3 A polymorphic CA repeat was characterised in the putative promoter sequence at position -2624 to -2587 of the sequence in Figure 2 . Briefly, 100 ng of patient DNA were amplified in 10 mM tris-HCl pH 8.3, 50 mM KCl, 200 µM dNTP, 1.5 mM MgCl 2 , with 10 pmoles of each primers, 1 nmole (3 µCi) of 32 P dCTP and 1 unit of Taq polymerase in a total volume of 25 µl. Thermocycling was carried out in the PTC-100 Programmable Thermal Controller (MJ Research, Inc., USA) at 94°C for 5 min followed by 30 cycles at 94°C for 10 s, 53°C for 10 s, 72°C for 10 s, and a final elongation step at 72°C for 5 min. After PCR, the products were denaturated at 94°C for 10 min with 6 µl of SSCP loading buffer (0.2 M NaOH, 0.25% w/v each bromophenol blue and xylene cyanol in formamide) and separated on a 6% native polyacrylamide gel. The sequence data described in this paper have been submitted to GenBank under accession numbers AF020663-AF020676.
Materials and Methods

Results and Discussion
The human MTM1 gene is composed of 15 exons ranging from 44 to 207 bp (Table 1) , the last exon been 223 or 1713 bp in length, depending on the polyadenylation signal used. 4 The predicted sizes of polyadenylated transcripts are about 3.6 and 2.1 kb, compared to the previously reported sizes of 3.9 and 2.4 kb observed on northern blots. This difference may result from experimental errors in sizing and/or reflects a 5' extension of the transcript with respect to the cloned cDNAs. This gene covers around 100 kb (between 96 and 104 kb) in the Xq28 proximal region. Exon 11 encodes the predicted tyrosine phosphatase active site and exon 1 is non-coding. Phase 0 introns (uninterrupted codon) are highly predominant (12 out of 13), whilst phase 1 (splice site after the first codon position) accounts for only one intron and phase 2 (splice site after the second nucleotide) is not present. Alternative spliced transcripts have not been reported so far, but if they exist, they will have a high chance of keeping the same open reading frame as the initial transcripts. Moreover, nucleotide changes affecting splice sites may still give a coding transcript lacking a portion of the protein if they lead to exon-skipping.
All of the exon-intron boundaries conform to the AG/GT rule, except for the donor site of exon 10 where a GC is found instead of GT in every patient and normal DNA analysed. This has already been described for a few other examples. 7 A polymorphism at position 1314 + 3 in the donor site of intron 11 was found, where A or G were equally present in the population, 6 and both nucleotides fit with the consensus sequence. The intronic sequences flanking the MTM1 exons and the sequence of the predicted promoter can now be used to derive primers and screen for mutations in patients, Because cis elements of a promoter are generally arrayed within a few hundred base pairs of the mRNA initiation site, we determined 2.7 kb of sequence directly upstream from exon 1 (Figure 2) . A polymorphism at position -110 was observed (T instead of C) in two patients (out of 60 patients tested) and in two normal X-chromosomes (out of 40 tested). One of the patients had already a frameshift mutation in exon 2 and the second had a mutation in exon 4 (patient N1-44 in ref 6 and unpublished data, Tanner SM, 1997, respectively).
Figure 1 Long range PCR analysis of the size of introns 2 and 6. Long range PCR was performed as described in methods using exon specific primers VN14 (5' A G A A C C T G TA A A G T A G T A C C 3') and VC113 (5'AGACTTCTCCTCAAGTTATGC3') for intron 2 (anneal
In the original description of the cDNA sequence, the location of the translation initiation site had not been determined. Moreover, an open reading frame of 426 nt is present proximal to the first cDNA base. 5' RACE experiments and numerous cDNA libraries screening with 5' probes led to several clones starting at position + 1 in Figure 2 . 4 RT-PCR using exon 1 primers amplified the expected product while nothing was amplified using primers proximal to position + 1 (not shown). More recent data using antibodies directed against myotubularin indicate that the endogenous protein is translated starting from the first methionine codon of the published cDNA sequence, corresponding to codon 19 (unpublished results, Laporte J, 1997).
The sequence between position -370 and the end of exon 1 is very GC-rich (73%) and exhibits rare CpG cutter sites (BssHII, EagI, NarI, NotI, SacII). It contains several predicted SP1 sites but no TATA-box or CAAT-box, as is often the case for a CpG island region upstream of a housekeeping gene. 10 The MTM1 gene has been shown to be ubiquitously expressed with an additional shorter transcript that uses a different polyadenylation signal in muscle and testis. 4 No eukaryotic pol II promoter was predicted by the GRAIL program although the TSSG BCM program 11 predicted with a very high score (LDF-33.10) a TATA-less promoter in the neighbourhood of exon 1 in the expected orientation, with a putative transcription start site at position + 37 of the MTM1 cDNA. Other transcription factor sites were predicted by the TESS program, 12 especially three myogenin binding sites, which might be important for muscle-specific transactivation and differentiation. Fifteen putative E-box (CANNTG) elements are present in the predicted promoter sequence and the MyoD transcription factor has been shown to specifically activate muscle genes by binding to the E-box. 13 As myotubular myopathy seems to be due to a defect in late myogenesis, the regulation of the MTM1 gene transcription or/and regulation of myotubularin activity might be an essential step toward the complete maturation of muscle fibres.
It is not uncommon that two genes start from the same CpG in opposite directions and several transcripts were reported in the neighbourhood of the MTM1 gene, 14 especially XAP83 located proximal. The sequence of the putative promoter did not detect ESTs in dbEST and no exons were predicted by GRAIL 15 and BCM 11 programs, with the exception of exon 1 Table 2 ). The predominant (CA)19 allele accounts for 54% of the chromosomes tested. The frequency of each allele is reported in Table 2 and the calculated heterozygosity is 65%. This new polymorphic marker, DXS9929, should prove useful for diagnosis by linkage analysis in familial cases, in combination with previously characterised DXS8377, DXS7423 and DXS1684. 16 DXS9929 is the closest characterised polymorphic marker from the MTM1 gene and may be more reliable than for example, DXS8377 which is located around 200 kb proximal, and was already found to recombine in an XLMTM family. 16 
